Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 25, 2016Leukemia & lymphoma/Leukemia and lymphoma

Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

HAHaifa Kathrin Al‐AliNovartis (Switzerland)VSViktoriya StalbovskayaMerus (Netherlands)PGPrashanth GopalakrishnaPfizer (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Al‐Ali et al. (2016) studied this question.

synapsesocial.com/papers/6a86c39b540b033b21bef0bbhttps://doi.org/10.3109/10428194.2016.1146950
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels2014 · 12 citations
  2. 2New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment2008 · 1,260 citations
  3. 3Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk2014 · 1 citations
  4. 4Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?2015 · 8 citations
  5. 5A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis2015 · 261 citations